Item 8.01 Other Events.

On November 9, 2016, EnteroMedics Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company had not regained compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2), within the 180 calendar day period ended November 7, 2016. In addition, on November 16, 2016, the Company received formal notice that it had not regained compliance with the $2.5 million stockholders’ equity requirement, as required by Nasdaq Listing Rule 5550(b), prior to the expiration of the extension period granted by the Staff on November 14, 2016.

On November 15, 2016, the Company requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the listing deficiencies. The Company’s request for a hearing has stayed any action by the Staff with respect to the Company’s continued listing on Nasdaq.

The Company previously disclosed via a Current Report on Form 8-K, as filed on May 13, 2016, that the Company had been notified by Nasdaq that it no longer satisfied (i) Listing Rule 5550(a)(2) because it did not evidence a closing bid price of at least $1.00 per share for the preceding 30 consecutive business days, and (ii) Listing Rule 5550(b) because it did not report stockholders’ equity of at least $2.5 million. By rule, the Company was granted a grace period through November 8, 2016 to regain compliance with the minimum bid price requirement. The Staff separately granted the Company an extension through November 14, 2016 to evidence compliance with the $2.5 million stockholders’ equity requirement based upon a compliance plan presented by the Company to the Staff. The Company intends to address both deficiencies at the hearing before the Panel, and will provide an update with respect to its listing status upon the receipt of relevant information from Nasdaq.

Story continues below


EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

ENTEROMEDICS INC. (NASDAQ:ETRM) Recent Trading Information

ENTEROMEDICS INC. (NASDAQ:ETRM) closed its last trading session up +0.0006 at 0.0535 with 5,947,184 shares trading hands.

An ad to help with our costs